These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 10351188)

  • 1. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.
    Samsa G; Edelman D; Rothman ML; Williams GR; Lipscomb J; Matchar D
    Pharmacoeconomics; 1999 Feb; 15(2):141-55. PubMed ID: 10351188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation.
    Ruchlin HS; Insinga RP
    Pharmacoeconomics; 2008; 26(11):925-35. PubMed ID: 18850762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials.
    Clayson DJ; Wild DJ; Quarterman P; Duprat-Lomon I; Kubin M; Coons SJ
    Pharmacoeconomics; 2006; 24(8):751-65. PubMed ID: 16898846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative review of generic quality-of-life instruments.
    Coons SJ; Rao S; Keininger DL; Hays RD
    Pharmacoeconomics; 2000 Jan; 17(1):13-35. PubMed ID: 10747763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of health status assessment measures in head and neck cancer: what do quality-of-life scores mean?
    Funk GF; Karnell LH; Smith RB; Christensen AJ
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):825-9. PubMed ID: 15262758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Linear Equating to Map PROMIS(®) Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3.
    Hays RD; Revicki DA; Feeny D; Fayers P; Spritzer KL; Cella D
    Pharmacoeconomics; 2016 Oct; 34(10):1015-22. PubMed ID: 27116613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring health-related quality of life in older patient populations: a review of current approaches.
    Hickey A; Barker M; McGee H; O'Boyle C
    Pharmacoeconomics; 2005; 23(10):971-93. PubMed ID: 16235972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it?
    Hays RD; Woolley JM
    Pharmacoeconomics; 2000 Nov; 18(5):419-23. PubMed ID: 11151395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linking the health utilities index to National Medical Expenditure Survey data.
    Rizzo JA; Pashko S; Friedkin R; Mullahy J; Sindelar JL
    Pharmacoeconomics; 1998 May; 13(5 Pt 1):531-41. PubMed ID: 10180752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using Health Utility Index (HUI) for measuring the impact on health-related quality of Life (HRQL) among individuals with chronic diseases.
    Mo F; Choi BC; Li FC; Merrick J
    ScientificWorldJournal; 2004 Aug; 4():746-57. PubMed ID: 15349514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
    Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
    Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life of young adults and adolescents with chronic kidney disease.
    Tong A; Wong G; McTaggart S; Henning P; Mackie F; Carroll RP; Howard K; Craig JC
    J Pediatr; 2013 Oct; 163(4):1179-85.e5. PubMed ID: 23800404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinically important difference on the unified Parkinson's disease rating scale.
    Shulman LM; Gruber-Baldini AL; Anderson KE; Fishman PS; Reich SG; Weiner WJ
    Arch Neurol; 2010 Jan; 67(1):64-70. PubMed ID: 20065131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reassessing quality-of-life instruments in the evaluation of new drugs.
    Guyatt GH; Jaeschke RJ
    Pharmacoeconomics; 1997 Dec; 12(6):621-6. PubMed ID: 10175974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Health Initiative Program for Kids (HIP Kids): effects of a 1-year multidisciplinary lifestyle intervention on adiposity and quality of life in obese children and adolescents--a longitudinal pilot intervention study.
    Bock DE; Robinson T; Seabrook JA; Rombeek M; Norozi K; Filler G; Rauch R; Clarson CL
    BMC Pediatr; 2014 Dec; 14():296. PubMed ID: 25475951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating health-related quality-of-life studies in paediatric populations: some conceptual, methodological and developmental considerations and recent applications.
    De Civita M; Regier D; Alamgir AH; Anis AH; Fitzgerald MJ; Marra CA
    Pharmacoeconomics; 2005; 23(7):659-85. PubMed ID: 15987225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic health-related quality-of-life assessment in children and adolescents: methodological considerations.
    Ravens-Sieberer U; Erhart M; Wille N; Wetzel R; Nickel J; Bullinger M
    Pharmacoeconomics; 2006; 24(12):1199-220. PubMed ID: 17129075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linking health-related quality-of-life indicators to large national data sets.
    Rizzo JA; Sindelar JL
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):473-82. PubMed ID: 10662394
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.